atacicept — Full data
Q3 2026
Alignment with FDA on earlier ORIGIN 3 final efficacy analysis to support potential full approval for TRUTAKNA in adults with IgAN; results expected in Q3 2026.Source filing
VERA biotech catalysts & pipeline
VERA THERAPEUTICS INC · Data as of 2026-09-08
Upcoming catalysts
TRUTAKNA™ (atacicept-vymj) — Topline data
Q3 2026
Final efficacy analysis from the ORIGIN 3 trial expected in Q3 2026Source filing
atacicept — Initial data
Q4 2026
In the Phase 2 PIONEER clinical trial, for which we expect to report additional results in the fourth quarter of 2026, we are evaluating atacicept in a broader population of IgAN patients as well as other autoimmune kidney diseases, including primary membranous nephropathy (pMN), focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD), in patients with anti-phospholipase A2 receptor or anti-nephrin autoantibodies.Source filing
TRUTAKNA™ (atacicept-vymj) — Topline data
Q4 2026
Additional PIONEER clinical results expected in Q4 2026Source filing
TRUTAKNA™ (atacicept-vymj) — NDA/BLA submission
Q4 2026
Anticipated sBLA submission to the FDA expected in Q4 2026Source filing
atacicept — Topline data
2027
2-year data from the pivotal ORIGIN 3 trial expected in 2027Source filing
TRUTAKNA™ (atacicept-vymj) — Regulatory decision
2027
Potential full approval of TRUTAKNA in IgAN expected in 2027Source filing